
|Videos|August 7, 2014
Chemotherapy Administration and Survival in Soft Tissue Sarcoma
Author(s)Sujana Movva, MD
Sujana Movva, MD, medical oncologist, Fox Chase Cancer Center, discusses an analysis of chemotherapy administration and survival in soft tissue sarcoma.
Advertisement
Clinical Pearls
Sujana Movva, MD, medical oncologist, Fox Chase Cancer Center, discusses an analysis of
- This was a National Cancer Database analysis looking at patterns of chemotherapy administration and survival in stage III soft tissue sarcoma (STS).
- Chemotherapy administration in this population of patients may vary across the country.
- This analysis showed an overall survival benefit for chemotherapy in stage III STS after adjusting for comorbidities.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
5









































